Subscribe to receive the latest in aesthetic medicine.
Get breaking developments, expert product comparisons, clinical roundtables, and practice strategies—all for free.
Valeant secures rights to market Refissa
Aliso Viejo, Calif. — Valeant Pharmaceuticals International, based here, has entered into an agreement with Spear Pharmaceuticals, Fort Myers, Fla., for the rights to commercialize Refissa (tretinoin cream, USP [emollient] 0.05 percent), a prescription topical cream used to treat fine wrinkles and irregular pigmentation due to sun damage, PR Newswire-FirstCall reports.
March 10, 2010
1 Min Read
Aliso Viejo, Calif. — Valeant Pharmaceuticals International, based here, has entered into an agreement with Spear Pharmaceuticals, Fort Myers, Fla., for the rights to commercialize Refissa (tretinoin cream, USP [emollient] 0.05 percent), a prescription topical cream used to treat fine wrinkles and irregular pigmentation due to sun damage, PR Newswire-FirstCall reports.
Valeant will pay Spear $12 million up front, and the companies will share net profits. Valeant will book sales and use its dermatology sales force to promote Refissa to dermatologists nationwide.
Feb 15 - Feb 17, 2025
Feb 15 - Feb 17, 2025
AMWC Americas offers evidence-based, cutting-edge scientific content, for all medical aesthetic practitioners. From nonsurgical to minimally invasive treatments, regenerative aesthetics, anti-aging therapies, sexual health, and personalized nutrition, this program covers it all! Plus, you'll gain valuable business and practice management education.
Learn More